Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy

Immune checkpoint inhibitors are new drugs approved for the treatment of many types of malignancies, such as lung cancer, melanoma and renal cancer. These monoclonal antibodies are directed against inhibitory immune receptors Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) (ipilimumab) and programmed cell death 1 (PD-1; nivolumab and pembrolizumab) and can improve the immune function of T-cells, resulting in significant clinical benefit in multiple cancer types. Despite their wide use and unquestionable clinical benefits, these agents have been also associated with a unique spectrum of side-effects known as immune-related adverse events (irAEs) [1].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research